Journal ArticleDOI
Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.Abstract:
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.read more
Citations
More filters
Journal ArticleDOI
cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells
TL;DR: N nanoparticles displaying the cIBR ligand may offer a useful targeted drug delivery system as an alternative treatment of inflammatory diseases involving transmigration of leukocytes.
Journal ArticleDOI
Fatty acid-spermine conjugates as DNA carriers for nonviral in vivo gene delivery.
Joana R Viola,H Leijonmarck,Oscar E. Simonson,Iulian I. Oprea,R Frithiof,Pasi Purhonen,Pedro Moreno,Karin E. Lundin,Roger Strömberg,C. I. E. Smith +9 more
TL;DR: A correlation between the in vitro properties of the ensuing DNA nanocarriers and their efficient in vivo gene expression is established, resulting in a significantly increased gene expression, in relation to naked plasmid, in both tissues herein targeted.
Journal ArticleDOI
A Novel Salted-out and Subsequently Crosslinked Poly(Lactic-co-Glycolic Acid) Polymeric Scaffold Applied to Monolithic Drug Delivery
TL;DR: In this paper, a statistical approach was used to develop a mechanistic understanding of the salting-out of poly(lactic-co-glycolic acid) and to evaluate the capacity to modulate the physicochemical and physicomechanical properties of PLGA by incorporating electrolytes that produce stochastic fluctuations.
Patent
Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
Jason Allan Wiles,Avinash Phadke,Milind Deshpande,Atul Agarwal,Dawei Chen,Venkat Rao Gadhachanda,Akihiro Hashimoto,Godwin Pais,Qiuping Wang,Xiangzhu Wang +9 more
TL;DR: The inhibitors of Factor D described in this article reduce the excessive activation of complement by reducing the activation ratio of the complement matrix to a small fraction of the normal value of the value.
Patent
Methods and compositions for attenuating anti-viral transfer vector immune responses
TL;DR: In this paper, methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants are presented for administering V2V and CARB.